50+ Presentations from Top Biopharma in 2026
In silico Approaches for siRNA AOC Optimisation
Josephine Alba, PhD, Senior Expert I Data Science, Biologics Research Center, Novartis Pharma AG
Long Acting, Stable Urocortin-2 Analogues for the Treatment of Obesity and Diabetes
Dennis Åsberg, PhD, Senior Project Manager, Global Research Technologies, Novo Nordisk A/S
Augmenting Biologics Drug Discovery with Deep Screening and Machine Learning
Mark J. Austin, PhD, Team Leader, Display Technology, CRUK AstraZeneca Antibody Alliance Laboratory
Targeting Peptides for Enhanced Tissue Delivery
Elise Bernard, PhD, Associate Principal Scientist, AstraZeneca
Building the Protein Lab of the Future at AstraZeneca: Automation First Science and AI Ready Data at Scale
Stan Blein, PhD, Senior Director and Head, Protein Sciences & Analytics, AstraZeneca
IVTT-Accelerated Protein Discovery: Generating Fit-for-Purpose AI Training Data
Frederikke Bjergvang Flagstad, Senior Automation Scientist, Cross Modality Workflows, Novo Nordisk AS
Toward in vivo Engineering of the Immune System
Adrian Bot, MD, PhD, Former CSO, Executive Vice President, R&D, Capstan Therapeutics
Real-World Progress, Challenges, and Opportunities for AI in Protein and Peptide Discovery
Peter Clark, PhD, Vice President, Computational Drug Design, Novo Nordisk Inc.
Advancing CD3 Bispecifics for Solid Tumour Indications
Alison Crawford, PhD, Director, Immuno-Oncology, Regeneron Pharmaceuticals
Engineering Affinity Attenuated and Effector CD8 Biased T Cell Engagers
Tilbe Creigh-Pulatmen, PhD, Assoc Dir, Protein Engineering & Novel Modalities - Oncology ICC, AstraZeneca
AI-Based Analysis of Label-Free Live Cell Imaging of T Cell Mediated Tumour Killing Assay Enables Competitive and Robust Hit Calling
Josefa dela Cruz-Chuh, Scientist 4, Biochemical and Cellular Pharmacology (BCP), Genentech
Generation of a Massive Dataset on VHH:Antigen Stability via High-Throughput (DMS) Experiments
Samuel Demharter, PhD, Senior Data Scientist, Discovery Data Science and Protein Science & Technologies, Genmab
Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumour Activity of CD3-Engaging Bispecific Antibodies
David J. DiLillo, PhD, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals
A Novel Antibody-Based Targeted Protein Degradation Platform for Immunology Indication
Feng Dong, PhD, Senior Principal Research Scientist, Immunology Discovery, AbbVie Cambridge Research Center
Robust Production of Virus-Like Particles in HEK293 Cell Lines
Alfred M. Engel, PhD, Teamlead, Cell Culture Technology, Roche Diagnostics GmbH
Integrating AI/ML and Next-Generation Sequencing for Accelerated Discovery of Single Domain Antibodies
Andreas Evers, PhD, Associate Scientific Director, Antibody Discovery & Protein Engineering, Global Research & Development Discovery Technology, Merck Healthcare KGaA
De novo VHH Design in Practice: Bridging AI Innovation with Real-World Biologics Design
Norbert Furtmann, PhD, Head, Biologics AI & Design, Large Molecules Research, Sanofi
What Have We Learned from a Decade of Research into Polysorbate Degradation?
Patrick Garidel, PhD, Head, Process, Purification, and Pharma Development, Biopharma, Boehringer Ingelheim Pharma GmbH
Multi-Objective Antibody Optimisation with Property Enhancer (PropEn)
Vladimir Gligorijević, PhD, Senior Director, AI/ML Prescient Design, Genentech
From Molecules to Drug Readiness
Tobias Grosskopf, PhD, Leader, F. Hoffmann-La Roche AG
Application of Expression Strategies for Integral Membrane Protein Production
Jenny Gunnarsson, Associate Principal Scientist, AstraZeneca
Insights into Fab Nebulisation: How to Minimise Aggregates for Inhaled Biologics
Marlon Hinner, PhD, Principal Scientist, pRED, Roche
Practical, Scalable Structure-Based Modelling for Rational Engineering of Multispecifics
Saeed Izadi, PhD, Director, Research Data Sciences, Gilead Sciences
A Novel Antibody Approach to Pan-Subclass IgG Reduction
Ibo Janssens, PhD, Senior Scientist, Preclinical Product Development, argenx BVBA
Comparative Analysis of 4-1BB and CD28 Tumour-Targeted Co-Stimulation to Support T Cell Bispecific Antibody Therapy in Solid Tumours
Teemu T. Junttila, PhD, Principal Scientist, Translational Oncology, Genentech
Empowering Next-Generation Antibodies: Synergy of Conditional Activation and Fc Engineering
Hitoshi Katada, PhD, Head of Biologics Engineering, Chugai Pharmaceutical Co. Ltd.
SMACk: A Modular Platform for Sterically Masked Activated Cytokines
James T. Koerber, PhD, Distinguished Scientist and Director, Antibody Engineering, Genentech, Inc.
Elucidating the Structure-PK Relationship of Complex Antibody Formats and Understanding the Underlying Mechanisms for Improved Drug Design
Thomas Kraft, PhD, Subchapter Lead, ADME, Senior Principal Scientist, F. Hoffmann La Roche AG
Decoding Photodegradation of ADC Payloads: Integrating in silico Modelling with Experimental Evidence to Understand and Predict Stability
Giuseppe L. Licari, PhD, Lead Scientist, Computational Structural Biology, Global Drug Product Development—BDC, Merck Serono SA
Next-Generation FVIIIa-Mimetic Bispecific Antibody NXT007 for Hemophilia A: Evaluation in Preclinical Models
Matthew Locke, PhD, Principal Scientist, Non-Malignant Hematology, Roche
Modelling Biparatopic Antibody Target Engagement and Pharmacology
James Lodge, Senior Scientist, Large Molecule Research, GSK
From Suspension to Signal: Enabling Analytical Characterisation of Therapeutic Proteins in High-Dose Non-Aqueous Suspension Formulations
Arnelle Loebbert, PhD, Postdoctoral Researcher, Novartis
Colloidal Stability Prediction of Multivalent NANOBODY Molecules Using Machine Learning
Eric Lorent, PhD, Principal Scientist, Sanofi
Mechanistic Understanding of an Unusually Stable Succinimide Intermediate in an Antibody Therapeutic
Goran Miličić, PhD, Senior Expert, Science & Technology, Novartis
Thermal Unfolding: From Heuristic Interpretation to Quantitative Models
Paul Molinaro, PhD, Postdoctoral Research Fellow, Biotherapeutic Development, Boehringer Ingelheim Pharma GmbH & Co. KG
Therapeutic Peptide Generative Models, Scoring Functions, and Retrosynthesis
Sridhar Neelamraju, PhD, Associate Principal Informatician, AstraZeneca
Precision-Activated T Cell Engagers in Immuno-Oncology: Pharmacological Characterisation of Albumin-Masked TCR Multispecific VHHs
Christelle Nonne, PhD, Senior Principal Scientist, LMR, Sanofi Group
Design of Potency Assays in Development of Standard and Complex Biologics
Petr Obrdlik, PhD, Associate Director, Analytical Development Bioanalytics, R&D, Novartis Biologics
T Cell Stimulating Vaccines Empower CD3 Bispecific Antibody Therapy in Solid Tumours
Vitaly Ovcinnikovs, PhD, Senior Scientist, Genmab
Methods and Technologies for Customisable Protein Expression in CHO Cells
Lindsey Pearson, PhD, Senior Scientist, Protein and Cellular Sciences, GSK
Multispecific T Cell Engagers and Co-Stimulation Combinations for the Treatment of Cancer Patients
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine
AI for Biologics: Transition from Discovery to Design
Yu Qiu, PhD, Executive Director, Biologics Design and Technology, AstraZeneca
Structural Biology at the Forefront of Biotherapeutics: Cryo-EM, AI, and Complex Modalities
Alexey Rak, PhD, Head, Biostructure and Biophysics, Sanofi
Next-Generation Protein Characterisation: An Integrated Mass Spectrometry Strategy from Structured Proteins to Intrinsically Disordered Proteins
Magdalena Richter, PhD, Associate Principal Scientist, AstraZeneca
AZD6750: Design and Efficacy of a CD8-Guided IL-2 that Enhances CD8+ T Cell Function
Aidan Riley, PhD, Associate Director, Biologics Engineering, Early Oncology, AstraZeneca
A Novel Approach to Enhance Tissue Specific Gene Delivery
Yang Shen, PhD, Executive Director, Antibody Engineering, Bispecifics, Regeneron
High-Throughput Automation Platform for Miniaturised Biophysical Assays: Accelerating Compound Screening with One Click
Gonçalo Silva, Senior Research Scientist, Biophysics & Injectable Formulation 1, Novo Nordisk A/S
Stability Prediction for Multispecific Antibodies
Roberto Spreafico, PhD, Senior Director, Biologics AI Innovation, AstraZeneca
Characterisation of a Biparatopic Sweeping Antibody
Jasmin Sydow-Andersen, PhD, Matrix & Science Lead LMR, Molecular Characterization, Roche Diagnostics GmbH
Machine Learning for Lead Optimisation Workflow (MeLLOw): Integrating in silico and Wet Lab Data for Biologics Engineering
Owen Vickery, PhD, Associate Principal Scientist, Augmented Biologics, AstraZeneca
Next-Generation T Cell Engagers: Leveraging Protease Activation to Overcome Toxicity and Expand the Therapeutic Window
Inja Waldhauer, PhD, Senior Principal Scientist, Roche Innovation Center Zurich
Molecular Dynamics Analysis toward Understanding Formulation-Dependent DSC Behaviour of Antibodies
Kota Yamaguchi, Research Scientist, Formulation Research, Injectable Technologies, Chugai Pharmaceutical Co. Ltd.
Strategy for Evaluating Undesired Mis-Paired Variants across Bispecific Antibody Modalities
Maki Yoshida, Deputy Head, Analytical Development Department, Pharmaceutical Technology Division, Chugai Pharmaceutical Co., Ltd.